NEA Eczema Awareness Month engages and enables the eczema community to unveil the realities of this chronic inflammatory skin disease that affects more than 31 million adults and children in the United States. United


This year’s one-month stakeholder engagement efforts focus on providing education, support and resources to people living with eczema through the ongoing #UnhideECZEMA campaign. NEA, and on raising awareness / awareness of the eczema experience through #GetEczemaWise, an empowerment campaign.

People of all races, ages, and skin types suffer from eczema, which refers to a group of chronic and acute symptoms that typically causes itchy skin, trouble sleeping, inflammation, and / or a rash-like appearance. cutaneous. There are seven different types of eczema and it is possible to have more than one. 3

Eczema has the largest effect on the life years associated with disability in patients with skin diseases worldwide.4 The disease burden of eczema includes a variety of painful and often debilitating physical, mental and emotional effects, as expressed in NEA Eczema Awareness Month Video.

Eczema facts

  • A recent study of adults with moderate to severe atopic dermatitis (AD), the most common form of eczema, found that 70.5% reported severe and unbearable itching in the past two weeks, 85.8 % reported itching daily and 62.8% reported itching for at least 12 hours per day. 5
  • Children and adolescents with AD are two to six times more likely to experience depression, anxiety or conduct disorders than children without AD. 6, 7
  • Recent studies have suggested that people with AD are up to 44% more likely to have suicidal thoughts and 36% more likely to attempt suicide. 8,9,10,11,12
  • One in four children and adolescents with AD have been bullied because of their disease. 12.13
  • Almost 5.9 million working days are lost each year due to eczema in United States. 14
  • The annual economic burden of eczema, including direct medical costs, indirect costs of lost productivity and impacts on quality of life, is cautiously estimated at $ 5.3 billion.15

Learn more about eczema:

At a time when people with eczema face additional challenges imposed by the coronavirus pandemic, the eczema community has reason to see hope on the horizon. “We are in the midst of an unprecedented era of discoveries and promise for the future of eczema, thanks to new drugs in development, ongoing scientific research and advancing knowledge about it. ‘lived experience and treatment preferences that may advance innovative and targeted therapies for this burdensome skin disease’, comments Julie bloc, President and CEO of NEA.

NEA Eczema Awareness Month 2020 is supported in part by the following sponsors: Sanofi Genzyme / Regeneron; AbbVie; Eli Lilly; Water wipes; baby dove; CeraVe and Dermavant.

About the National Eczema Association (NEA)
Founded in 1988, the NEA is America’s largest 501 (c) (3) nonprofit patient advocacy organization serving people with eczema. The NEA’s mission is to improve the health and quality of life of people with eczema through research, support and education. To learn more about the NEA, visit:

The references

  1. Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A population survey on the prevalence of eczema in United States. Dermatitis. 2007; 18 (2): 82-91.
  2. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013; 132 (5): 1132-1138.
  3. More than Skin Deep Collaborative. (2020). Understanding the Lived Experience of Eczema: The Patient’s Voice Report on the Patient-Centered Drug Development Meeting for Eczema. Recovered from
  4. Karimkhani C, Dellavalle RP, Coffeng LE, et al. Global Morbidity and Mortality from Skin Disease: Update of the Global Burden of Disease Study 2013. JAMA Dermatol. 2017; 153 (5): 406-412.
  5. Simpson EL, Bieber T, Eckert L, et al. Burden of moderate to severe atopic dermatitis (AD) patients: overviews of a phase 2b adult clinical trial of dupilumab. J Am Acad Dermatol. 2016; 74 (3): 491-498
  6. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013; 131 (2): 428-433.
  7. Garg N, Silverberg JI. Association between childhood allergic diseases, psychological comorbidity and injuries requiring medical attention. Ann Allergy Asthma Immunol. 2014; 112 (6): 525-532.
  8. Sandhu JK, Wu KK, Bui TL, Armstrong AW. Association between atopic dermatitis and suicidal tendencies: a systematic review and meta-analysis. JAMA Dermatol. 2019; 155 (2): 178-187.
  9. Patel KR, Immaneni S, Singam V, Rastogi S, Silverberg JI. Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis. J Am Acad Dermatol. 2019; 80 (2): 402-410.
  10. Ronnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol. 2018; 79 (3): 448-456 e430.
  11. Drucker AM, Thiruchelvam D, Redelmeier DA. Eczema and subsequent suicide: a matched case-control study. BMJ Open. 2018; 8 (11): e023776.
  12. Halvorsen J., Lien L, Dalgard F, Bjertness E, Stern RS. Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study. J Invest Dermatol. 2014; 134 (7): 1847-1854.
  13. Magin P, Adams J, Heading G, Pond D, Smith W. Appearance-related teasing and bullying experiences in skin diseases and their psychological sequelae: results of a qualitative study. Scand J Caring Sci. 2008; 22 (3): 430-436.
  14. Silverberg JI. Health care utilization, patient costs, and access to care among American adults with eczema: a population-based study. JAMA Dermatol. 2015; 151 (7): 743-752.
  15. Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. J Invest Dermatol. 2017; 137 (1): 26-30.

SOURCE National Eczema Association

Related links

Source link


Comments are closed.